APPENDIX D 
NONTECHNICAL ABSTRACT OF PROTOCOL 
This protocol is designed for patients with advanced neuroblastoma that have 
not had success with other treatments. For these patients, a new approach for 
treating their cancer will be tested. 
The patient's cancer cells will be removed from their bone marrow and grown 
up in the laboratory. There, the gene for a cancer fighting protein (interleukin-2) will 
be put in the cancer cells. The interleukin-2 gene causes these cancer cells to 
produce interleukin-2. The treated cells will be placed under the patient's skin. When 
these cells are returned to the patient, they will release interleukin-2. Interleukin-2 
activates cancer-killing cells in the body. A week later the patient will be treated with 
a larger number of these cells if there was no problem with the first treatment. Since 
this therapy is new, it is not known how well it will work in people. The doctors will 
look for signs that the cancer-killing cells are working by looking at the place where 
the cells were placed under the skin of the patient, as well as measuring cancer-killing 
cells in the blood. They will also look at how well this treatment is working by 
measuring the size of the patient's tumor. The patient will be carefully watched 
during the entire treatment for possible harmful effects. It is hoped that this protocol 
will tell the doctors how safe it is to return these cancer cells that release interleukin- 
2, how many cells can be returned safely, and if there are any signs that this new 
treatment is helping the patient fight their cancer. With this information, the doctors 
may be able to develop better ways to help other people fight their cancer. 
[774] 
Recombinant DNA Research, Volume 15 
